MEK/ERK inhibitors: proof-of-concept studies in lung fibrosis

Andrew Leask

Received: 21 November 2011 / Accepted: 22 November 2011 / Published online: 1 December 2011
© The International CCN Society 2011

Abstract There is no therapy for chronic fibroproliferative diseases, in spite of the fact that current health statistics suggest that these (which include cardiovascular disease, pulmonary fibrosis, diabetic nephropathy, liver cirrhosis and systemic sclerosis) have been estimated to cause approximately 45% of the deaths in the developed world. Recently, many studies have shown that mitogen activated protein kinases (MAPKs) are activated in response to fibrogenic agents and contribute to the formation and function of the myofibroblast, the critical cell type responsible for excessive scarring. A recent report by Madala and colleagues (Am J Respir Cell Mol Biol, 2011) has provided a proof-of-concept study showing that the specific MEK inhibitor ARRY-142886 (ARRY) can both suppress the progression of fibrosis and reverse an animal model of lung fibrosis. Thus MEK inhibition could be a valuable method to treat lung fibrosis.

Keywords ctgf · ccn2 · mek/erk · Iloprost · Scleroderma · Lung fibrosis

TGF β induces fibrogenic responses through the canonical Alk5/Smad3/4 pathway; yet, the MAPK cascade, including the ras/MEK/ERK pathway are also involved (Leask 2010; Chen et al. 2005). In particular, TGF β induces (for example) CCN2, matrix contraction and collagen expression (Leask et al. 2003; Chen et al. 2005, 2008, 2011; Wang et al. 2006; Samuel et al. 2010). Moreover, the compound iloprost,

which has some antifibrotic ability in vivo and in vitro blocks TGF β -induced ERK activation (Stratton et al. 2001, 2002; Zhu et al. 2010; Stratton and Newton 2010). The transcription factors that act downstream of ERK appear to be ets-1 and Smad 1 (Pannu et al. 2007; van Beek et al. 2006; Mott et al. 2011).

Recent evidence has shown that ERK activation is increased in the bleomycin model of lung fibrosis and PD98059 blocks the fibrosis observed (Galuppo et al. 2011). Moreover, in a separate model of fibrosis, in which TGF α is overexpressed by lung epithelia using a doxycycline-dependent system, ERK is also activated; a novel MER inhibitor ARRY-142886 (ARRY) was both able to prevent the onset of fibrosis as well as to reverse established fibrosis (Madala et al. 2011), including TGF α -induced lung cell proliferation and matrix gene production.

It is interesting to note that TGF β -induced CCN2 expression depends on ERK (Stratton et al. 2002; Leask et al. 2003). Moreover, CCN2-dependent fibrosis also relies on ERK (Ponticos et al. 2009; Sonnylal et al. 2010; Nakerakanti et al. 2011). Although the following specific hypothesis was not evaluated in the recent studies using ERK inhibitors, it is plausible that ERK inhibition may prevent fibrosis by blocking the action of CCN2 in vivo.

References

- Chen Y, Shi-Wen X, van Beek J, Kennedy L, McLeod M, Renzoni EA, Bou-Gharios G, Wilcox-Adelman S, Goetinck PF, Eastwood M, Black CM, Abraham DJ, Leask A (2005) Matrix contraction by dermal fibroblasts requires transforming growth factor-beta/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK/ERK: insights into pathological scarring in chronic fibrotic disease. Am J Pathol 167(6):1699–711

A. Leask (✉)
Departments of Dentistry and Physiology and Pharmacology,
University of Western Ontario,
Dental Sciences Building,
London, ON, Canada N6A 5C1
e-mail: Andrew.leask@schulich.uwo.ca

- Chen Y, Leask A, Abraham DJ, Pala D, Shiwen X, Khan K, Liu S, Carter DE, Wilcox-Adelman S, Goetinck P, Denton CP, Black CM, Pitsillides AA, Sarraf CE, Eastwood M (2008) Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts. *Arthritis Rheum* 58:577–85
- Chen Y, Leask A, Abraham DJ, Kennedy L, Shi-Wen X, Denton CP, Black CM, Verjee LS, Eastwood M (2011) Thrombospondin 1 is a key mediator of transforming growth factor β -mediated cell contractility in systemic sclerosis via a mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK)-dependent mechanism. *Fibrogenesis Tissue Repair* 4(1):9
- Galuppo M, Esposito E, Mazzone E, Di Paola R, Paterniti I, Impellizzeri D, Cuzzocrea S (2011) MEK inhibition suppresses the development of lung fibrosis in the bleomycin model. *Naunyn-Schmiedeberg Arch Pharmacol* 384(1):21–37
- Leask A (2010) Potential therapeutic targets for cardiac fibrosis: TGF β , angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. *Circ Res* 106(11):1675–80
- Leask A, Holmes A, Black CM, Abraham DJ (2003) Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor- β 2 in fibroblasts. *J Biol Chem* 278(15):13008–15
- Madala SK, Schmidt S, Davidson C, Ikegami M, Wert S, Hardie WD (2011) MEK-ERK pathway modulation ameliorates pulmonary fibrosis associated with epidermal growth factor receptor activation. *Am J Respir Cell Mol Biol*, 2011 Oct 20
- Mott GA, Costales JA, Burleigh BA (2011) A soluble factor from *Trypanosoma cruzi* inhibits transforming growth factor- β -induced MAP kinase activation and gene expression in dermal fibroblasts. *PLoS One* 6(9):e23482
- Nakerakanti SS, Bujor AM, Trojanowska M (2011) CCN2 is required for the TGF- β induced activation of Smad1-Erk1/2 signaling network. *PLoS One* 6(7):e21911
- Pannu J, Nakerakanti S, Smith E, ten Dijke P, Trojanowska M (2007) Transforming growth factor- β receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. *J Biol Chem* 282:10405–13
- Ponticos M, Holmes AM, Shi-wen X, Leoni P, Khan K, Rajkumar VS, Hoyle RK, Bou-Gharios G, Black CM, Denton CP, Abraham DJ, Leask A, Lindahl GE (2009) Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. *Arthritis Rheum* 60(7):2142–55
- Samuel GH, Bujor AM, Nakerakanti SS, Hant FN, Trojanowska M (2010) Autocrine transforming growth factor β signaling regulates extracellular signal-regulated kinase 1/2 phosphorylation via modulation of protein phosphatase 2A expression in scleroderma fibroblasts. *Fibrogenesis Tissue Repair* 3:25
- Sonnlyal S, Shi-Wen X, Leoni P, Naff K, Van Pelt CS, Nakamura H, Leask A, Abraham D, Bou-Gharios G, de Crombrughe B (2010) Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis. *Arthritis Rheum* 62(5):1523–32
- Stratton R, Newton F (2010) Commentary on a recent article—“A prostacyclin analogue, iloprost, protects from bleomycin-induced fibrosis in mice” Zhu Y et al. *Respir Res*, 2010 Mar 20;11(1):34. *J Cell Commun Signal* 4(4):187–8
- Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T, Martin GR, Black CM, Abraham D (2001) Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. *J Clin Invest* 108(2):241–50
- Stratton R, Rajkumar V, Ponticos M, Nichols B, Shiwen X, Black CM, Abraham DJ, Leask A (2002) Prostacyclin derivatives prevent the fibrotic response to TGF- β by inhibiting the Ras/MEK/ERK pathway. *FASEB J* 16(14):1949–51
- Van Beek JP, Kennedy L, Rockel JS, Bernier SM, Leask A (2006) The induction of CCN2 by TGF β 1 involves Ets-1. *Arthritis Res Ther* 8(2):R36
- Wang Z, Fong KD, Phan TT, Lim IJ, Longaker MT, Yang GP (2006) Increased transcriptional response to mechanical strain in keloid fibroblasts due to increased focal adhesion complex formation. *J Cell Physiol* 206(2):510–7
- Zhu Y, Liu Y, Zhou W, Xiang R, Jiang L, Huang K, Xiao Y, Guo Z, Gao J (2010) A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice. *Respir Res* 11:34